Cancer Frontline - June 2013 | MD Anderson Cancer Center Skip to Content
Top

BY MD Anderson Staff

MD Anderson scientists have found a molecular signaling pathway that connects two known contributors to cancer cell growth and survival. They also showed that the active signaling network shortens survival of breast cancer patients.

The epidermal growth factor receptor (EGFR) tells the protein MCM7, through an intermediary, to fire up the very first step of DNA replication leading to cell growth, the researchers report in the June...

BY Laura Sussman

MET protein levels correlate strongly with a cellular transition that occurs in a treatment-resistant type of colorectal cancer, according...

BY Will Fitzgerald

In a large national, cooperative trial led by MD Anderson, researchers determined bevacizumab (Avastin), did not offer survival benefit to...

BY Laura Sussman

Following surgery, radiation and chemotherapy with a drug that hinders formation of tumor-supporting blood vessels does not increase the survival of glioblastoma patients, according to a phase III clinical trial.

Results of the first randomized, double-blind clinical trial of the drug bevacizumab (Avastin) for newly diagnosed glioblastoma patients were presented at the American Society of...